Volume 4, Issue 2 (Autumn & Winter 2016 2017)                   Jorjani Biomed J 2017, 4(2): 48-57 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Shakerizadeh S, Shekari M, Nejatizadeh A, Poursadegh zonouzi A, fardmanesh H, Poursadegh zonouzi A. Investigation of Exportin 5 (XPO5) mRNA expression in breast cancer patients. Jorjani Biomed J. 2017; 4 (2) :48-57
URL: http://goums.ac.ir/jorjanijournal/article-1-474-en.html
Associate Professor Molecular Medicine Research Center ,Hormozgan University of Medical Sciences, Bandar Abbas, Iran , mshekariomics@gmail.com
Abstract:   (1986 Views)

Background and objectives: Deregulation in the expression of microRNAs is involved in the pathogenesis of various malignancies. Impaired microRNAs processing pathway is one possible mechanism for global deregulation of the miRNAs. Exportin 5 (XPO5) is a key member of this pathway that links nuclear and cytoplasmic steps of miRNAs biogenesis together. XPO5 deregulation has been reported in some cancers but very little is known about its role in breast cancer. Therefore, this study aimed to evaluate the mRNA expression of XPO5 in breast cancer in an Iranian population.

Methods: In this case-control study, 30 tumoral tissues and 30 tumor-free margins were collected from breast cancer patients. After RNA extraction and cDNA synthesis, XPO5 mRNA expression level was assessed using quantitative Real-Time PCR.

Results: Our results showed that XPO5 was overexpressed in 53.3% of tumoral tissues but the difference in the gene expression level between tumoral tissues and tumor-free margins was not statistically significant (P-value=0.834). XPO5 expression level showed no statistically significant correlation and association with clinical and pathological parameters.

Conclusion: Overexpression of XPO5 in large percent of patients indicates that high level of XPO5 expression may be a tumorigenic factor for breast cancer which needs to be investigated more deeply.

Full-Text [PDF 811 kb]   (971 Downloads)    
Type of Study: Original paper | Subject: General
Received: 2016/12/26 | Accepted: 2016/12/26 | Published: 2016/12/26

1. Haji HA, Khoshnazar AK, Gherati R, Javan B, Asadi J. valproic acid and radiation therapy effects on MCF-7 breast cancer cell line viability. Journal of Gorgan University of medical sciences. 2014;16(3(. (persian)
2. Shiri Y, Aghaalinejad H, Gharakhanloo R, Shalamzari SA, Saee M. study of 6 weeks endurance training effect on IL-10 level in breast tumor tissue of female mouses. Iran metabolism and endocrinology journal. 2014;16(3):205-10.(persian)
3. Sheikhpour R, Taghipourzoheir S. study of codon 27 polymorphism of P53 gene and resulting protein in women with breast cancer in Yazd. Iran breast diseases. 2014;7(3 ((persian )
4. Heneghan H, Miller N, Lowery A, Sweeney K, Kerin M. MicroRNAs as novel biomarkers for breast cancer. Journal of oncology. 2009;2010
5. Takahashi R-u, Miyazaki H, Ochiya T. The Roles of MicroRNAs in Breast Cancer. Cancers. 2015;7(2):598-616
6. Friedman RC, Farh KK-H, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome research. 2009;19(1):92-105
7. Bajan S, Hutvagner G. Regulation of miRNA Processing and miRNA Mediated Gene Repression in Cancer. Microrna (Shariqah, United Arab Emirates). 2014;3(1):10
8. Melo SA, Esteller M. Dysregulation of microRNAs in cancer: playing with fire. FEBS letters. 2011;585(13):2087-99
9. Romero-Cordoba SL, Salido-Guadarrama I, Rodriguez-Dorantes M, Hidalgo-Miranda A. miRNA biogenesis: biological impact in the development of cancer. Cancer biology & therapy. 2014;15(11):1444-55
10. Davis-Dusenbery BN, Hata A. microRNA in Cancer The involvement of aberrant microRNA biogenesis regulatory pathways. Genes & cancer. 2010;1(11):1100-14
11. Hata A, Lieberman J. Dysregulation of microRNA biogenesis and gene silencing in cancer. Science signaling. 2015;8(368):re3
12. Bouyssou JM, Manier S, Huynh D, Issa S, Roccaro AM, Ghobrial IM. Regulation of microRNAs in cancer metastasis. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2014;1845(2):255-65
13. Deng S, Calin GA, Croce CM, Coukos G, Zhang L. Mechanisms of microRNA deregulation in human cancer. Cell cycle. 2008;7(17):2643-6
14. Melo SA, Esteller M, editors. Disruption of microRNA nuclear transport in human cancer. Seminars in cancer biology; 2014: Elsevier
15. Yi R, DOEHLE BP, Qin Y, MACARA IG, CULLEN BR. Overexpression of exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs. Rna. 2005;11(2):220-6
16. Melo SA, Moutinho C, Ropero S, Calin GA, Rossi S, Spizzo R, et al. A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer cell. 2010;18(4):303-15
17. Iwasaki YW, Kiga K, Kayo H, Fukuda-Yuzawa Y, Weise J, Inada T, et al. Global microRNA elevation by inducible Exportin 5 regulates cell cycle entry. Rna. 2013;19(4):490-7
18. Huang J-T, Wang J, Srivastava V, Sen S, Liu S-M. MicroRNA machinery genes as novel biomarkers for cancer. Frontiers in oncology. 2014;4
19. Leaderer D, Hoffman AE, Zheng T, Fu A, Weidhaas J, Paranjape T, et al. Genetic and epigenetic association studies suggest a role of microRNA biogenesis gene exportin-5 (XPO5) in breast tumorigenesis. International journal of molecular epidemiology and genetics. 2011;2(1):9
20. Catto JW, Miah S, Owen HC, Bryant H, Myers K, Dudziec E, et al. Distinct microRNA alterations characterize high-and low-grade bladder cancer. Cancer research. 2009;69(21):8472-81
21. Mach C, Kim J, Anderson M. Loss of miR-143 promotes the proliferation of UPSC by enhancing exportin-5 expression. Gynecologic Oncology. 2012;125:S161
22. Boni V, Zarate R, Villa J, Bandres E, Gomez M, Maiello E, et al. Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. The pharmacogenomics journal. 2011;11(6):429-36
23. Guo Z, Wang H, Li Y, Li B, Li C, Ding C. A microRNA‑related single nucleotide polymorphism of the XPO5 gene is associated with survival of small cell lung cancer patients. Biomedical reports. 2013;1(4):545-8
24. Ding C, Li C, Wang H, Li B, Guo Z. A miR-SNP of the XPO5 gene is associated with advanced non-small-cell lung cancer. OncoTargets and therapy. 2013;6:877
25. Heneghan HM, Miller N, Kerin MJ. MiRNAs as biomarkers and therapeutic targets in cancer. Current opinion in pharmacology. 2010;10(5):543-50
26. Han Y, Liu Y, Gui Y, Cai Z. Inducing cell proliferation inhibition and apoptosis via silencing Dicer, Drosha, and Exportin 5 in urothelial carcinoma of the bladder. Journal of surgical oncology. 2013;107(2):201-5
27. Chiosea S, Jelezcova E, Chandran U, Luo J, Mantha G, Sobol RW, et al. Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer research. 2007;67(5):2345-50

Add your comments about this article : Your username or Email:

Send email to the article author

© 2018 All Rights Reserved | Jorjani Biomedicine Journal

Designed & Developed by : Yektaweb